Treatment Patterns, Effectiveness, and Safety of Originator Insulin Glargine versus Insulin Glargine-yfgn within the Veterans Health Administration

• Main Authors: Samantha Walczuk (Author), Francesca E. Cunningham (Author), Xinhua Zhao (Author), Diane Dong (Author), Peter A. Glassman (Author), Donald R. Miller (Author), Deborah Khachikian (Author), Anthony Au (Author), Cedric Salone (Author), Kelly Bryan (Author), Qoua Her (Author), Sherrie L. Aspinall (Author)
• Format: Book
• Published: MDPI AG, 2024-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

We described insulin glargine (originator) and insulin glargine-yfgn (biosimilar) treatment patterns, assessed effectiveness and safety outcomes, and identified reasons for switching back to the originator product from the biosimilar. This retrospective study included 328,463 Veterans 18 years of ag...